<DOC>
	<DOCNO>NCT01920568</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy study design provide bridge data Asian population Amgen 's study denosumab subject bone metastasis solid tumor . The study design provide data large global dataset phase-III study include breast cancer , prostate cancer , solid tumor , plus multiple myeloma , support regulatory approval marketing patient access denosumab prevention SREs Chinese subject bone metastasis solid tumor . The primary objective study evaluate compare percent change baseline Week 13 bone marker urinary amino-terminal cross-linking telopeptide type I collagen ( uNTx ) correct urine creatinine ( uNTx/uCr ) subject treat denosumab treat zoledronic acid . The study design test superiority denosumab zoledronic acid .</brief_summary>
	<brief_title>A Study Compare Denosumab With Zoledronic Acid Subjects With Bone Metastases From Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Subject understand nature purpose study study procedure , explain Investigator delegate , subject sign write informed consent overall study . The subject must sign separate write informed consent eligible enrolment pharmacokinetic substudy . Adult ( age &gt; =18 year ) Asian ancestry histologically cytologically confirm solid tumor . In addition , subject enrol center mainland China SFDAcertified center Hong Kong include approximately 33 subject pharmacokinetic substudy must Chinese race , ancestry , heritage . Subjects enrol region country , Taiwan Singapore , nonSFDAcertified center Hong Kong , require Chinese race ancestry . Current prior documented radiographic evidence ( i.e. , xray , computer tomography [ CT ] , magnetic resonance image [ MRI ] ) least 1 bone metastasis . Female subject childbearing potential must negative serum urine pregnancy test within 7 day first dose study treatment agree use effective contraception , define , study 6 month end study treatment . Women report pregnancy study follow birth outcome . GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device intrauterine system documented failure rate le 1 % per year ; Male partner sterilization prior female subject 's enrollment male sole sexual partner subject ; information male sterility come site personnel 's review subject 's medical record ; medical examination subject and/or semen analysis ; interview subject medical history ; complete abstinence sexual intercourse 14 day prior first dose study treatment , dose period , least 7 month last dose study treatment ; doublebarrier contraception : male condom combine female diaphragm , either without vaginal spermicide ( foam , gel , film , cream , suppository ) ; implant levonorgestrel etonogestrel contraindicate patient population per local practice ; injectable progesterone contraindicate patient population per local practice ; percutaneous contraceptive patch contraindicate patient population per local practice ; Oral contraceptive ( either combine progesterone ) contraindicate patient population per local practice . Females child bear potential male partner part prefer usual lifestyle require use contraception . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ( refer protocol detail ) . Adequate baseline organ function define follow criterion : Serum aspartate aminotransferase ( AST ) &lt; =2.0 x upper limit normal ( ULN ) ; Serum alanine aminotransferase ( ALT ) &lt; =2.0 x ULN ; Serum total bilirubin &lt; =1.0 x ULN ; creatinine clearance ( calculate use CockcroftGault formula ) &gt; =30 milliliter per minute ( mL/min ) ; serum calcium albuminadjusted serum calcium &gt; =2.0 millimole per liter ( mmol/L ) ( 8.0 mg/dL ) &lt; =2.9 mmol/L ( 11.5 miligram per deciliter [ mg/dL ] ) . Subjects must take supplemental calcium least 8 hour prior collection blood sample screen serum calcium determination . Life expectancy least 6 month , opinion Investigator . Any serious and/or unstable preexist medical , psychiatric disorder , condition , opinion Investigator , could interfere subject 's safety , obtain informed consent compliance study procedure ; The Investigator consult GSK Medical Monitor prior enrol subject s/he unsure condition might interfere subject 's safety participation study . Any prior treatment intravenous ( IV ) oral bisphosphonates . Prior treatment denosumab . Planned radiation therapy surgery bone . Known brain metastasis . Prior history current evidence osteomyelitis osteonecrosis jaw ( ONJ ) , active dental jaw condition require oral surgery , nonhealed dental oral surgery , plan invasive dental procedure course study . Evidence follow condition per subject self report medical chart review : prior current malignancy ( cancer study protocol ) active disease within 3 year randomization ; unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) ; know infection human immunodeficiency virus ( HIV ) ; active infection hepatitis B hepatitis C virus . Pregnant woman , woman plan become pregnant within 7 month end study treatment , woman breastfeed . Women breast feeding discontinue nurse prior first dose study treatment refrain nursing throughout treatment period 7 month follow last dose study treatment . Male subject unable unwilling use adequate contraception method study 6 month end study treatment exclude . Subject currently enrol another investigational device investigational product study , complete least 30 day , 5 half life , duration biological effect , whichever longer , since end study . Known sensitivity investigational product supplement administer study ( i.e. , zoledronic acid , mammalian derive product , calcium , vitamin D ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GSK2371746</keyword>
	<keyword>Denosumab</keyword>
	<keyword>China</keyword>
	<keyword>skeletal-related event</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>bridging study</keyword>
	<keyword>solid tumor</keyword>
</DOC>